Clinical Trials

94 enrolled

Neuroendocrine Tumors

NCT06406465 2026-03-18

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

60 enrolled

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03412877 2026-03-17

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

18 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT04750954 2026-03-17

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Phase 1 Active not recruiting

29 enrolled

Neuroendocrine Tumors

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

29 enrolled

Neuroendocrine Tumors

NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Phase 1 Completed

83 enrolled 13 charts

Neuroendocrine Tumors

NCT07087054 2026-03-10

CAREFNDR

141 enrolled

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT07129252 2026-03-10

BRAVESST2

150 enrolled

Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02568267 2026-03-06

STARTRK-2

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

534 enrolled 1 FDA

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT05918302 2026-03-06

LEVEL

120 enrolled

Thymus Neoplasms, Neuroendocrine Tumors

NCT03211988 2026-03-02

Entinostat Neuroendocrine (NE) Tumor

Phase 2 Terminated

5 enrolled 9 charts

Recurrence, Neuroendocrine Tumors

NCT04969887 2026-02-27

MOST-CIRCUIT

240 enrolled

Genital Neoplasms, Female, Neuroendocrine Tumors

NCT06943755 2026-02-27

STELLAR-311

Phase 2/3 Recruiting

440 enrolled

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT04074135 2026-02-24

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

740 enrolled

von Hippel-Lindau Disease, Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT04907643 2026-02-20

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

360 enrolled

Cancer Pain, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Stomach Neoplasms, Neuroendocrine Tumors, Visceral Pain

NCT07377487 2026-02-20

INDIGO

51 enrolled

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Carcinoma, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Colorectal Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Suspended

29 enrolled

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03206060 2026-02-17

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

130 enrolled

CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT07404176 2026-02-11

TENET

20 enrolled

Neoplasms, Neuroendocrine Tumors

NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

800 enrolled

CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

NCT04104529 2026-02-05

BCB RIV

EndocrineGenitourinaryHead & NeckNET

350 enrolled

Prostatic Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors

NCT04459273 2026-02-05

FAPI PET RDRC

Phase 1 Active not recruiting

26 enrolled

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther hematologic neoplasm

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Unknown Primary, Skin Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Hematologic Neoplasms

NCT04954820 2026-02-05

ReLUTH

146 enrolled

Neuroendocrine Tumors, Disease Progression

NCT06055439 2026-01-29

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

135 enrolled

Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

EndocrineGastrointestinalGenitourinaryNET

27 enrolled

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT07366658 2026-01-26

NEUK203-13

Phase 1 Not yet recruiting

9 enrolled

BreastEndocrineGastrointestinalGenitourinaryNET

Neuroendocrine Tumors

NCT04373564 2026-01-22

ODYSSEY

Phase 4 Recruiting

2,076 enrolled

Breast Neoplasms, Carcinoma, Hepatocellular, Prostatic Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

NCT05477576 2026-01-20

ACTION-1

288 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06122610 2026-01-15

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

10 enrolled

Neuroendocrine Tumors

NCT04362436 2026-01-14

ArTisaN

Phase 2 Completed

24 enrolled

Neuroendocrine Tumors

NCT05987176 2026-01-14

NELMAS

Phase 2 Terminated

1 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT06232564 2026-01-14

PELICAN

20 enrolled

Neuroendocrine Tumors

NCT03950609 2026-01-09

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

36 enrolled

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT06788886 2025-12-30

Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases

CNSEndocrineGenitourinaryNET

147 enrolled

Brain Neoplasms, Multiple Sclerosis, Prostatic Neoplasms, Neuroendocrine Tumors

NCT06881992 2025-12-30

Tumor HI

Phase 1 Active not recruiting

16 enrolled

EndocrineNETSarcoma

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT04234568 2025-12-22

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

31 enrolled 16 charts

Neuroendocrine Tumors

NCT07272512 2025-12-19

ZSPAC-17

Phase 4 Recruiting

350 enrolled

Neuroendocrine Tumors

NCT03728361 2025-12-18

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

55 enrolled

EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04086485 2025-12-17

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

56 enrolled

Carcinoid Tumor, Neuroendocrine Tumors

NCT06441331 2025-12-17

KinLET

CNSEndocrineGastrointestinalLymphoidNETSarcoma

20 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroendocrine Tumors

NCT06889493 2025-12-17

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

36 enrolled

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06926634 2025-12-17

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

32 enrolled

Neuroendocrine Tumors

NCT06943521 2025-12-11

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

BreastEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETSarcomaThoracic

27 enrolled

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Endometrial Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04339036 2025-12-10

CapTemY90

70 enrolled